MENU
PHAR
AS OF
Feb 4, 03:25 PM (EDT)
Price
$16.86
Change
-$0.41 (-2.38%)
Capitalization
1.18B
36 days until earnings call
Intraday BUY SELL Signals
+Compare
PHAR
Stock ticker: NASDAQ
AS OF
Feb 4, 03:25 PM (EDT)
Price
$16.86
Change
-$0.41 (-2.38%)
Capitalization
1.18B

PHAR Pharming Group NV Forecast, Technical & Fundamental Analysis

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases... Show more

PHAR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PHAR with price predictions
Feb 03, 2026

Aroon Indicator for PHAR shows an upward move is likely

PHAR's Aroon Indicator triggered a bullish signal on January 28, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 142 similar instances where the Aroon Indicator showed a similar pattern. In of the 142 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PHAR moved out of overbought territory on January 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where PHAR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on February 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAR as a result. In of 120 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PHAR turned negative on February 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 64 similar instances when the indicator turned negative. In of the 64 cases the stock turned lower in the days that followed. This puts the odds of success at .

PHAR moved below its 50-day moving average on February 02, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PHAR broke above its upper Bollinger Band on January 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHAR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.515) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (3.544) is also within normal values, averaging (331.843).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
PHAR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PHAR is expected to report earnings to fall 55.00% to 4 cents per share on March 12

Pharming Group NV PHAR Stock Earnings Reports
Q4'25
Est.
$0.05
Q3'25
Beat
by $0.10
Q2'25
Beat
by $0.07
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.07
The last earnings report on November 06 showed earnings per share of 10 cents, beating the estimate of 0 cents. With 4.12K shares outstanding, the current market capitalization sits at 1.18B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Darwinweg 24
Phone
+31 715247400
Employees
332
Web
https://www.pharming.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DVMFX38.040.40
+1.06%
Invesco Developing Markets R5
PSVIX16.510.14
+0.86%
Virtus NFJ Small-Cap Value Inst
TSWEX13.53N/A
N/A
TSW Large Cap Value Institutional
GPTUX13.43-0.04
-0.30%
GuidePath® Tactical Allocation Svc
MTCLX72.12-2.26
-3.04%
MFS Technology R6

PHAR and Stocks

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
+1.68%
APLM - PHAR
31%
Poorly correlated
-10.24%
ANTX - PHAR
29%
Poorly correlated
-3.57%
ADPT - PHAR
27%
Poorly correlated
+0.60%
IBRX - PHAR
27%
Poorly correlated
+3.26%
RNAC - PHAR
25%
Poorly correlated
+2.06%
More